Osimertinib in ResectedEGFR-Mutated Non–Small-Cell Lung Cancer
Author(s) -
YiLong Wu,
Masahiro Tsuboi,
Jie He,
Thomas John,
Christian Grohé,
Margarita Majem,
Jonathan W. Goldman,
К. К. Лактионов,
SangWe Kim,
Terufumi Kato,
Huu-Vinh Vu,
Shun Lü,
Kye Young Lee,
Charuwan Akewanlop,
ChongJen Yu,
Filippo de Marinis,
Laura Bonanno,
Manuel Dómine,
Frances A. Shepherd,
Lingmin Zeng,
Rachel Hodge,
Ajlan Atasoy,
Yuri Rukazenkov,
Roy S. Herbst
Publication year - 2020
Publication title -
new england journal of medicine
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa2027071
Subject(s) - osimertinib , lung cancer , medicine , cancer research , oncology , cancer , epidermal growth factor receptor , erlotinib
Osimertinib is standard-of-care therapy for previously untreated epidermal growth factor receptor ( EGFR ) mutation-positive advanced non-small-cell lung cancer (NSCLC). The efficacy and safety of osimertinib as adjuvant therapy are unknown.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom